Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Depression 4Anxiety Disorders 3Pancreatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fatigue 1

Interventions

pembrolizumab 4Oncolytic Virotherapy 4Cisplatin 4Cetuximab 3Radiotherapy 2Positron Emission Tomography Computed Tomography 2Nivolumab 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Fluorouracil 2Erlotinib Hydrochloride 2Docetaxel 2technetium 99m ethylenedicysteine deoxyglucose 1ruxolitinib 1dornase alfa 1avelumab 1alovudine 1Varenicline 1VTX-2337 1Tobacco Use Cessation Devices 1Tetrahydrouridine 1TAK-981 1Ropivacaine 1Raltegravir Potassium 1Pyrimethamine 1Postmortem Imaging 1Positron-Emission Tomography 1Paclitaxel 1Oxycodone 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Head and Neck Neoplasms × Ketamine × Clear all
NCT02442739 2018-11-06

Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

Cedars-Sinai Medical Center

Phase EARLY_PHASE1 Withdrawn
GastrointestinalHead & Neck

Depression, Head and Neck Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡